ADI responds to results of EXPEDITION3 study by Eli Lilly

23 November 2016 - Alzheimer’s Disease International (ADI) has noted the announcement of Phase 3 clinical trial results today that suggest negative results of the drug solanezumab by Eli Lilly and Company. More details will be presented at the CTAD conference on 8 December in San Diego. However there are many more treatments being tested and we can still do a lot to improve the lives of millions of people living with Alzheimer’s disease and other dementias.

There are almost 50 million people living with dementia worldwide, of whom 60-70% are living with Alzheimer’s disease. Most individuals with the disease, even in highly developed health systems, remain undiagnosed and do not receive any treatment. With one new case of dementia somewhere in the world every three seconds, there is an urgent need to improve our health systems and respond to their needs.

Glenn Rees, ADI chair says: “We regret the dissappointing results of this potentially disease modifying drug but note that there are still another 15-18 drugs in final development stage. People with Alzheimer’s disease and other dementias can receive symptomatic drug treatment as well as non-medical treatments and social support that enable them to maintain a quality of life for as long as possible. Therefore it is imperative that health systems gear up to identify persons with cognitive impairment and help patients manage their lives. But we also need our societies to become more inclusive and dementia friendly to all those with the condition.”

A draft World Health Organization (WHO) Global plan on dementia also addresses the main issues in dementia policy – including detection and diagnosis and improved access to available treatments and support. It takes a whole of government approach and links to other key work streams of WHO activity including the plans for NCDs, Mental Health and Ageing.

ADI urges that further research is needed to get a better understanding of the role of new drugs, including potential disease modifying treatments.

Where next?